Fontaine R, Beaudry P, Beauclair L, Chouinard G
Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(2-3):189-97. doi: 10.1016/0278-5846(87)90059-5.
In a 8-week double-blind placebo controlled study, 48 outpatients with generalized anxiety disorder were randomized to diazepam, buspirone, a non-benzodiazepine anxiolytic, or placebo. During the treatment phase of 4 weeks duration diazepam was found to be significantly better than placebo and buspirone. Following abrupt withdrawal by placebo substitution the diazepam group showed a gradual relapse maximal after two weeks while the buspirone and the placebo groups did not differ. There were more cases of rebound anxiety with diazepam as compared to buspirone or placebo. In addition, there were three early terminations related to rebound anxiety in the diazepam group while there were none in the placebo and buspirone groups. There were significantly more new symptoms in the diazepam group than in the placebo or buspirone group.
在一项为期8周的双盲安慰剂对照研究中,48名广泛性焦虑症门诊患者被随机分为接受地西泮、丁螺环酮(一种非苯二氮䓬类抗焦虑药)或安慰剂治疗。在为期4周的治疗阶段,发现地西泮的疗效显著优于安慰剂和丁螺环酮。在通过安慰剂替代突然停药后,地西泮组出现逐渐复发,在两周后达到最大复发程度,而丁螺环酮组和安慰剂组之间没有差异。与丁螺环酮或安慰剂相比,地西泮组出现反跳性焦虑的病例更多。此外,地西泮组有3例因反跳性焦虑而提前终止治疗,而安慰剂组和丁螺环酮组均无此类情况。地西泮组出现的新症状明显多于安慰剂组或丁螺环酮组。